Daejeon, South Korea

Myung-ho Sohn


 

Average Co-Inventor Count = 9.9

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Myung-ho Sohn: Innovator in Bioscience and Biotechnology

Introduction

Myung-ho Sohn is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of bioscience and biotechnology, particularly through his innovative patents. With a total of 3 patents to his name, Sohn's work focuses on developing solutions for inflammatory diseases and cancer diagnostics.

Latest Patents

One of his latest patents is related to CD93, which involves an anti-inflammatory composition using an antibody that specifically binds to CD93 or its soluble fragment. This invention also includes a diagnostic method and kit for inflammatory diseases utilizing the specific antibody or aptamer targeting CD93. Another notable patent is the TMPRSS4-specific human antibody, which pertains to a transmembrane protease, serine (TMPRSS4)-specific human antibody. This invention is particularly relevant for diagnosing various types of cancer, classifying diseases, and aiding in treatment and prognostic evaluation.

Career Highlights

Myung-ho Sohn is affiliated with the Korea Research Institute of Bioscience and Biotechnology, where he continues to advance research in his field. His work has garnered attention for its potential applications in medical diagnostics and therapeutic interventions.

Collaborations

Sohn collaborates with notable colleagues, including Young Woo Park and Jae Won Jeon, who contribute to his research endeavors and innovations.

Conclusion

Myung-ho Sohn's contributions to bioscience and biotechnology exemplify the impact of innovative thinking in addressing critical health challenges. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…